Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

65
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
65
Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

471
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
471
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

449
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
449
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.5K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.5K
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

78
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
78
Pharmacodynamic Models: Linear Concentration–Effect Model01:15

Pharmacodynamic Models: Linear Concentration–Effect Model

56
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...
56

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How physiology solves the gene-centric impasse.

Experimental physiology·2026
Same author

Age-related changes in lysosomal abundance in mouse hearts assessed by Lysotracker fluorescence imaging and autophagy gene expression analysis.

The international journal of cardiovascular imaging·2026
Same author

Translational strategy to support the first-in-human study of a TCR-like T cell bispecific with an <i>in vitro</i>-based safety approach.

Frontiers in immunology·2026
Same author

Generation and applications of cardiac spheroids.

npj biomedical innovations·2026
Same author

The principles of systems biology.

Experimental physiology·2026
Same author

Guideline-based strategies to identify severe cytokine release syndrome in COVID-19 and cancer immunotherapy using large-scale electronic health records.

Frontiers in digital health·2026

Related Experiment Video

Updated: Mar 25, 2026

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
10:39

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Published on: April 15, 2017

13.8K

Recent developments in using mechanistic cardiac modelling for drug safety evaluation.

Mark R Davies1, Ken Wang2, Gary R Mirams3

  • 1QT-Informatics, Macclesfield, UK.

Drug Discovery Today
|February 20, 2016
PubMed
Summary

A new initiative combines in vitro and in silico methods to enhance cardiac proarrhythmic safety assessment. This approach integrates computational tools with experimental tests for improved drug safety evaluations.

More Related Videos

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
10:30

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Published on: August 4, 2022

3.7K
Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

2.7K

Related Experiment Videos

Last Updated: Mar 25, 2026

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
10:39

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Published on: April 15, 2017

13.8K
Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
10:30

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Published on: August 4, 2022

3.7K
Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

2.7K

Area of Science:

  • Pharmacology
  • Computational Biology
  • Cardiovascular Science

Background:

  • The tenth anniversary of International Conference on Harmonisation (ICH) guidelines for cardiac proarrhythmic safety highlights the need for updated risk assessment strategies.
  • Current methods for evaluating drug-induced cardiac risks require enhancement to improve predictive accuracy.

Purpose of the Study:

  • To review the Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative, which integrates in vitro and in silico technologies.
  • To compare and contrast state-of-the-art computational and experimental tools for cardiac electrophysiology risk assessment.
  • To outline how these tools can be combined for improved compound decision-making in drug development.

Main Methods:

  • Review of existing empirical and mechanistic models of cardiac electrophysiology.
  • Analysis of in vitro assay technologies relevant to cardiac safety.
  • Evaluation of in silico computational approaches for predicting proarrhythmic effects.

Main Results:

  • The CiPA initiative represents a significant advancement in utilizing computational tools for regulatory decision-making in cardiac safety.
  • A combination of in vitro and in silico methods offers a more comprehensive approach to cardiac risk assessment than traditional methods.
  • The review details the integration of various models and experimental tests for robust compound evaluation.

Conclusions:

  • The integration of in vitro and in silico technologies, as exemplified by the CiPA initiative, is crucial for advancing cardiac proarrhythmic safety assessment.
  • Computational tools, when combined with experimental data, can significantly improve the accuracy and efficiency of drug safety evaluations.
  • This paradigm shift is essential for regulatory decision-making and ensuring patient safety.